tradingkey.logo
tradingkey.logo
Buscar

Tempus AI Inc

TEM
Añadir a la lista de seguimiento
49.860USD
+0.390+0.79%
Cierre 05/08, 16:00ETCotizaciones retrasadas 15 min
8.95BCap. mercado
PérdidaP/E TTM

Más Datos de Tempus AI Inc Compañía

Tempus AI, Inc. is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. It offers AI-enabled precision medicine solutions to physicians to deliver personalized patient care and, in parallel, facilitates discovery, development and delivery of optimal therapeutics. It provides three product lines: Genomics, Data and artificial intelligence applications (AI). The Genomics product line leverages its laboratories to provide next generation sequencing (NGS) diagnostics, polymerase chain reaction, profiling, molecular genotyping and other anatomic and molecular pathology testing. The data generated in its lab or ingested into its platform is structured and de-identified, prior to commercialization. Its AI Applications is focused on developing and providing diagnostics that are algorithmic in nature, implementing new software as a medical device, and building and deploying clinical decision support tools.

Información de Tempus AI Inc

Símbolo de cotizaciónTEM
Nombre de la empresaTempus AI Inc
Fecha de salida a bolsaMay 30, 2025
Director ejecutivoLefkofsky (Eric P)
Número de empleados2400
Tipo de seguridadOrdinary Share
Fin del año fiscalMay 30
Dirección600 West Chicago Avenue
CiudadCHICAGO
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal60654
Teléfono18335144187
Sitio Webhttps://investors.tempus.com/
Símbolo de cotizaciónTEM
Fecha de salida a bolsaMay 30, 2025
Director ejecutivoLefkofsky (Eric P)

Ejecutivos de Tempus AI Inc

Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Ryan Fukushima
Mr. Ryan Fukushima
Chief Operating Officer
Chief Operating Officer
859.70K
+4.91%
Mr. Peter J. Barris
Mr. Peter J. Barris
Independent Director
Independent Director
106.73K
+3.77%
Mr. Andrew (Andy) Polovin
Mr. Andrew (Andy) Polovin
Executive Vice President, General Counsel, Company Secretary
Executive Vice President, General Counsel, Company Secretary
28.98K
+81.75%
Mr. James (Jim) Rogers
Mr. James (Jim) Rogers
Chief Financial Officer
Chief Financial Officer
26.91K
+79.62%
Mr. Eric D. Belcher
Mr. Eric D. Belcher
Independent Director
Independent Director
20.76K
+29.15%
Dr. Scott Gottlieb, M.D.
Dr. Scott Gottlieb, M.D.
Independent Director
Independent Director
14.80K
+91.55%
Mr. David R. Epstein
Mr. David R. Epstein
Independent Director
Independent Director
11.02K
+70.57%
Mr. Eric P. Lefkofsky, J.D.
Mr. Eric P. Lefkofsky, J.D.
Chairman of the Board, Chief Executive Officer, Founder
Chairman of the Board, Chief Executive Officer, Founder
--
--
Mr. Erik J. Phelps, J.D.
Mr. Erik J. Phelps, J.D.
Executive Vice President, Chief Administrative and Legal Officer, Assistant Secretary
Executive Vice President, Chief Administrative and Legal Officer, Assistant Secretary
--
--
Dr. Jennifer A. Doudna, Ph.D.
Dr. Jennifer A. Doudna, Ph.D.
Independent Director
Independent Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Ryan Fukushima
Mr. Ryan Fukushima
Chief Operating Officer
Chief Operating Officer
859.70K
+4.91%
Mr. Peter J. Barris
Mr. Peter J. Barris
Independent Director
Independent Director
106.73K
+3.77%
Mr. Andrew (Andy) Polovin
Mr. Andrew (Andy) Polovin
Executive Vice President, General Counsel, Company Secretary
Executive Vice President, General Counsel, Company Secretary
28.98K
+81.75%
Mr. James (Jim) Rogers
Mr. James (Jim) Rogers
Chief Financial Officer
Chief Financial Officer
26.91K
+79.62%
Mr. Eric D. Belcher
Mr. Eric D. Belcher
Independent Director
Independent Director
20.76K
+29.15%
Dr. Scott Gottlieb, M.D.
Dr. Scott Gottlieb, M.D.
Independent Director
Independent Director
14.80K
+91.55%

Desglose de ingresos

La empresa aún no ha revelado los datos relevantes.
La empresa aún no ha revelado los datos relevantes.
Por negocio
Por región
La empresa aún no ha revelado los datos relevantes.

Estadísticas de accionistas

Actualizado: hace 2 horas
Actualizado: hace 2 horas
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Blue Media, LLC
9.05%
BK TL21 LLC
7.36%
Lefkofsky (Eric Paul)
7.19%
ARK Investment Management LLC
5.41%
Gray Media, LLC
5.09%
Otro
65.90%
Accionistas
Accionistas
Proporción
Blue Media, LLC
9.05%
BK TL21 LLC
7.36%
Lefkofsky (Eric Paul)
7.19%
ARK Investment Management LLC
5.41%
Gray Media, LLC
5.09%
Otro
65.90%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor
33.96%
Corporation
26.11%
Investment Advisor/Hedge Fund
10.97%
Individual Investor
8.02%
Hedge Fund
4.75%
Research Firm
4.00%
Holding Company
3.10%
Bank and Trust
1.09%
Venture Capital
0.89%
Otro
7.10%

Participación institucional

Actualizado: mié., 1 de abr
Actualizado: mié., 1 de abr
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2026Q1
847
109.28M
62.62%
+6.29M
2025Q4
746
95.93M
55.50%
+4.67M
2025Q3
619
75.72M
43.81%
-4.20M
2025Q2
501
136.83M
81.41%
-3.18M
2025Q1
444
136.54M
81.24%
-3.30M
2024Q4
259
141.87M
89.45%
+26.80M
2024Q3
171
136.39M
89.94%
+26.38M
2024Q2
115
132.44M
88.72%
+132.44M

Actividad de los accionistas

Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Blue Media, LLC
16.19M
9.32%
-1.95M
-10.74%
Dec 31, 2025
BK TL21 LLC
15.22M
8.76%
--
--
Mar 18, 2025
Lefkofsky (Eric Paul)
12.77M
7.35%
+249.84K
+2.00%
Feb 20, 2026
ARK Investment Management LLC
9.45M
5.44%
+1.89M
+24.99%
Feb 28, 2026
Gray Media, LLC
8.97M
5.17%
-299.25K
-3.23%
Dec 31, 2025
Baillie Gifford & Co.
8.74M
5.03%
-951.00K
-9.81%
Dec 31, 2025
Red Sky LLC
8.06M
4.64%
-1.44M
-15.13%
Sep 30, 2025
Catalytic Wealth RIA, LLC
6.76M
3.89%
+6.76M
--
Dec 31, 2025
BlackRock Institutional Trust Company, N.A.
6.04M
3.47%
+652.41K
+12.12%
Dec 31, 2025
SoftBank Group Corp
5.41M
3.11%
--
--
Dec 31, 2025
Ver más

ETFs relacionados

Actualizado: sáb., 6 de dic
Actualizado: sáb., 6 de dic
Nombre
Proporción
ARK Genomic Revolution ETF
12.02%
ARK Innovation ETF
5.1%
Global X HealthTech ETF
4.22%
Franklin Genomic Advancements ETF
3.92%
Renaissance IPO ETF
3.83%
KraneShares Artificial Intelligence and Tcnlgy ETF
3.05%
AXS Green Alpha ETF
2.92%
ROBO Global Artificial Intelligence ETF
2.49%
First Trust Health Care Alphadex Fund
2.42%
Innovator IBD 50 Fund ETF
2.22%
Ver más
ARK Genomic Revolution ETF
Proporción12.02%
ARK Innovation ETF
Proporción5.1%
Global X HealthTech ETF
Proporción4.22%
Franklin Genomic Advancements ETF
Proporción3.92%
Renaissance IPO ETF
Proporción3.83%
KraneShares Artificial Intelligence and Tcnlgy ETF
Proporción3.05%
AXS Green Alpha ETF
Proporción2.92%
ROBO Global Artificial Intelligence ETF
Proporción2.49%
First Trust Health Care Alphadex Fund
Proporción2.42%
Innovator IBD 50 Fund ETF
Proporción2.22%

Dividendos

Un total de 0.00 USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos

División de acciones

Fecha
Fecha ex-dividendo
Tipo
Relación
Sin datos
Fecha
Fecha ex-dividendo
Tipo
Relación
Sin datos
KeyAI